In the News
Genomic Health to market Epic Sciences’ AR-V7 liquid biopsy test.
New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.
Test aids prostate cancer treatment.
New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.
Guest Commentary: Back to cancer’s drawing board.
By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.
Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.
Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.
Epic, Avera ink deal to use liquid biopsy platform in clinical studies.
New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.
Never leave a cell behind.
Rocky River, DDNews — Article covering Epic Sciences' platform technology and describes how it is being used in partnerships with outside research teams.
Utility of CTC platform in prostate cancer MDx.
New York, GenomeWeb — Epic Sciences was covered in a “Featured In-Depth” story in GenomeWeb Daily News: "Epic Sciences, MSKCC Research Suggests Utility for CTC Platform in Prostate Cancer MDx."